{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:49Z","timestamp":1793830909756,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003135","name":"Minnesota Ovarian Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ygyno.2013.01.010","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T15:46:21Z","timestamp":1358955981000},"page":"81-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: A pilot study"],"prefix":"10.1016","volume":"129","author":[{"given":"Peter A.","family":"Argenta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanasak","family":"Sueblinvong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Jonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Levi S.","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda F.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.01.010_bb0170","series-title":"Principles and practice of gynecologic oncology","year":"2009"},{"issue":"3","key":"10.1016\/j.ygyno.2013.01.010_bb0175","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ygyno.2013.01.010_bb0015","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ygyno.2013.01.010_bb0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.01.010_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ygyno.2013.01.010_bb0180","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.01.010_bb0185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/978-3-642-83260-4_29","article-title":"Summary of recent clinical experience in whole-body hyperthermia combined with chemotherapy","volume":"107","author":"Engelhardt","year":"1988","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"10.1016\/j.ygyno.2013.01.010_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/1096-9098(200005)74:1<41::AID-JSO10>3.0.CO;2-R","article-title":"Treatment of peritoneal carcinomatosis with intent to cure","volume":"74","author":"Cavaliere","year":"2000","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.01.010_bb0040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/030089160108700302","article-title":"Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study","volume":"87","author":"Deraco","year":"2001","journal-title":"Tumori"},{"issue":"3C","key":"10.1016\/j.ygyno.2013.01.010_bb0045","first-page":"3019","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin","volume":"23","author":"de Bree","year":"2003","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ygyno.2013.01.010_bb0190","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2006.10.051","article-title":"Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma","volume":"105","author":"Helm","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2B","key":"10.1016\/j.ygyno.2013.01.010_bb0055","first-page":"1329","article-title":"Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy","volume":"22","author":"Panteix","year":"2002","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.ygyno.2013.01.010_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jso.20243","article-title":"Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma","volume":"90","author":"Reichman","year":"2005","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2013.01.010_bb0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejso.2006.03.011","article-title":"Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced\/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan","volume":"32","author":"Raspagliesi","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2013.01.010_bb0070","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jso.20597","article-title":"Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer","volume":"94","author":"Rufian","year":"2006","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.01.010_bb0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/bjc.1994.45","article-title":"Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin","volume":"69","author":"Los","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2013.01.010_bb0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00685503","article-title":"Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy","volume":"28","author":"Los","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.01.010_bb0085","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2009.08.028","article-title":"Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model","volume":"115","author":"Jandial","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.01.010_bb0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00262768","article-title":"Potnetiation of platinum analogue cytotoxicity by hyperthermia","volume":"21","author":"Xu","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.01.010_bb0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ygyno.2007.03.022","article-title":"Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma","volume":"106","author":"Lentz","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.01.010_bb0100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s002800050870","article-title":"A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer","volume":"43","author":"Steller","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.01.010_bb0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer. Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"10 Suppl.","key":"10.1016\/j.ygyno.2013.01.010_bb0110","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.01.010_bb0120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/djj018","article-title":"Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection","volume":"98","author":"Schrag","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.01.010_bb0125","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejso.2010.04.012","article-title":"Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer","volume":"36","author":"Woelber","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ygyno.2013.01.010_bb0130","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00423-011-0835-2","article-title":"Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned","volume":"396","author":"K\u00f6nigsrainer","year":"2011","journal-title":"Langenbecks Arch Surg"},{"issue":"2","key":"10.1016\/j.ygyno.2013.01.010_bb0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2009.05.004","article-title":"Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome","volume":"114","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.01.010_bb0140","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jamcollsurg.2012.04.023","article-title":"Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy","volume":"215","author":"Votanopoulos","year":"2012","journal-title":"J Am Coll Surg"},{"issue":"12","key":"10.1016\/j.ygyno.2013.01.010_bb0145","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results","volume":"135","author":"Chua","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.01.010_bb0150","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/annonc\/mdm137","article-title":"Systematic review of cytoreductive surgery and heated intra-operative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer","volume":"18","author":"Bijelic","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.01.010_bb0155","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.03.004","article-title":"Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study","volume":"113","author":"Fagotti","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.01.010_bb0200","unstructured":"Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol in press. [Epub UID 22825772]."},{"issue":"1","key":"10.1016\/j.ygyno.2013.01.010_bb0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2005.07.123","article-title":"Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon","volume":"100","author":"Aletti","year":"2006","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:32:55Z","timestamp":1758771175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0090825813000206"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.01.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}